scholarly journals Developing an Evidence Base for the Delivery of Hepatitis B Virus Birth Dose Vaccination: An Evidence Map and Critical Appraisal of Systematic Reviews and Guidelines

2021 ◽  
Vol 17 (5) ◽  
pp. 375-381
Author(s):  
Stephanie Doran Brubaker ◽  
John W. Ward ◽  
Lindsey Hiebert ◽  
Rebecca L. Morgan
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Systematic Reviews ◽  
Critical Appraisal ◽  
Evidence Base ◽  
Evidence Map ◽  
B Virus ◽  
Birth Dose

scholarly journals Arresting Vertical Transmission of Hepatitis B Virus (AVERT-HBV) in the Democratic Republic of the Congo

2021 ◽  
Author(s):  
Peyton Thompson ◽  
Camille E. Morgan ◽  
Patrick Ngimbi ◽  
Kashamuka Mwandagalirwa ◽  
Noro Ravelomanana ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Pregnant Women ◽  
Democratic Republic ◽  
Sub Saharan Africa ◽  
Pmtct Program ◽  
B Virus ◽  
Birth Dose ◽  
Republic Of The Congo ◽  
Dose Vaccine

Background: Hepatitis B virus (HBV) remains endemic throughout sub-Saharan Africa despite the widespread availability of effective vaccines. We evaluated the feasibility of adding HBV testing and treatment of pregnant women and birth-dose vaccination of HBV-exposed infants to the HIV prevention of MTCT (PMTCT) program infrastructure in the Democratic Republic of the Congo (DRC), where HBV treatment and birth-dose vaccination programs are not established. Methods: As part of the HIV PMTCT program at two maternity centers in Kinshasa, DRC, pregnant women were screened for HBV at routine prenatal care registration. Pregnant women with high viral load and/or HBeAg positivity were offered tenofovir disoproxil fumarate (TDF). HBV-exposed infants received a birth-dose of HBV vaccine within 24 hours of life. The primary endpoint was the feasibility and acceptability of the study. Results: Of 4,016 women screened, 109 (2.7%) were HBsAg-positive. Ten of 91 (11.1%) women evaluated had high-risk disease. Of 88 infants, 60 (68.2%) received a birth-dose vaccine; of these, 46 (76.7%) received a timely birth-dose. No cases of HBV MTCT were observed in our cohort. There were no serious adverse events associated with TDF nor with birth-dose vaccine. The study procedures were highly acceptable (>80%) among mothers. Conclusions: Adding HBV screening and treatment of pregnant women and infant birth-dose vaccination to existing HIV PMTCT platforms is feasible in countries like the DRC. Birth-dose vaccination against HBV integrated within the current Expanded Programme on Immunization (EPI) and HIV PMTCT program could accelerate progress toward HBV elimination in Africa.

scholarly journals Introduction of birth dose of hepatitis B virus vaccine to the immunization program in Ethiopia: an economic evaluation

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Solomon Tessema Memirie ◽  
Hailemichael Desalegn ◽  
Mulugeta Naizgi ◽  
Mulat Nigus ◽  
Lisanu Taddesse ◽  
...  
Keyword(s):  
Economic Evaluation ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Virus Vaccine ◽  
Immunization Program ◽  
B Virus ◽  
Birth Dose ◽  
Hepatitis B Virus Vaccine

scholarly journals Analysis of Factors and Management of Hepatitis B Virus Screening in Mothers and Infants: A Scoping Review

2020 ◽  
Author(s):  
◽  
Nurul Kurniati ◽  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Early Detection ◽  
Scoping Review ◽  
Critical Appraisal ◽  
Perinatal Transmission ◽  
Hbv Infection ◽  
Inclusion Criteria ◽  
B Virus ◽  
Virus Screening

ABSTRACT Background: The importance of screening for HBV infection is to identify the risk of perinatal transmission from infected mothers. People infected with HBV during infancy or childhood are more likely to suffer chronic infection to cirrhosis of the liver and liver cancer. Early detection and prompt treatment are essential for HBV infection. This study aimed to review the factors and management of hepatitis B virus screening in mothers and infants. Subjects and Method: A scoping review method was conducted in eight stages including (1) Identification of study problems; (2) Determining priority problem and study question; (3) Determining framework; (4) Literature searching; (5) Article selec­tion; (6) Critical appraisal; (7) Data extraction; and (8) Mapping. The search included PubMed, ScienceDirect, Wiley Online Library, and Scopus databases. The inclusion criteria were English/ Indonesian-language and full-text articles (scoping review, meta-analysis, systematic review)/ documents/ reports/ policy brief/ guidelines from WHO/ other organizations published between 2009 and 2019. The data were selected by the PRISMA flow chart. Results: The searched database obtained a total of 27.862 articles. After screening, 27.325 articles were excluded because of unmet the inclusion criteria. After conducting critical appraisal for the remaining 537 articles, only 11 articles were eligible for further review. The selected articles obtained from developing countries (China, South Africa, and Tanzania) and developed countries (Netherlands, Japan, Denmark, Northern Europe, and Canada) with quantitative studies design (cross-sectional, case series, and cohort) met the inclusion criteria. The findings emphasized on four main topics around hepatitis B virus screening in mothers and infants, namely demographic factors, risk factors, post-screening benefit, and challenges in screening uptake. Conclusion: Early detection of HBV infection with prenatal screening reduce the HBV prenatal transmission, especially from infected pregnancy. Screening plays an important role in the administration of universal infant HBV vaccination and postexposure prophylaxis with hepatitis B immune globulin (HBIG) at birth. Keywords: pregnant women, hepatitis B virus, perinatal transmission, screening Correspondence: Setianingsih. Universitas ‘Aisyiyah Yogyakarta. Jl. Siliwangi (Ringroad Barat) No. 63, Nogotirto, Gamping, Sleman, Yogyakarta, 55292. Email: [email protected]. Mobile: 082242081295. DOI: https://doi.org/10.26911/the7thicph.03.67

scholarly journals Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study

2018 ◽  
Vol 6 (6) ◽  
pp. e659-e667 ◽  
Author(s):  
Nick Scott ◽  
Anna Palmer ◽  
Christopher Morgan ◽  
Olufunmilayo Lesi ◽  
C Wendy Spearman ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
B Virus ◽  
Birth Dose ◽  
Dose Vaccine ◽  
Modelling Study

Increased Protection of Earlier Use of Immunoprophylaxis in Preventing Perinatal Transmission of Hepatitis B Virus

2020 ◽  
Author(s):  
Hongyu Huang ◽  
Chenyu Xu ◽  
Lanhua Liu ◽  
Liping Chen ◽  
Xiaoqin Zhu ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Newborn Infants ◽  
Perinatal Transmission ◽  
Hbv Dna ◽  
Hepatitis B Vaccine ◽  
B Virus ◽  
Birth Dose ◽  
Protection Efficacy ◽  
Immunoprophylaxis Failure

Abstract Background Passive-active immunoprophylaxis against mother-to-child transmission (MTCT) of hepatitis B virus (HBV) recommends administering hepatitis B immunoglobulin (HBIG) and birth-dose hepatitis B vaccine in infants within 12 or 24 hours after birth. With this protocol, MTCT of HBV still occurs in 5–10% infants of HBV-infected mothers with positive hepatitis B e antigen (HBeAg). The present study aimed to investigate whether earlier administration of HBIG and hepatitis B vaccine after birth can further increase protection efficacy. Methods We conducted a prospective, multi-center observational study in infants born to mothers with HBV infection, in whom neonatal HBIG and birth dose hepatitis B vaccine were administered within one hour after birth. The infants were followed up for HBV markers at 7–14 months of age. Results A total of 1140 pregnant women with HBV were enrolled, and 982 infants (9 twins) of 973 mothers were followed up at 9.6 ± 1.9 months of age. HBIG and birth-dose vaccine were administered in newborn infants within a median of 0.17 (0.02–1.0) hours after birth. The overall rate of MTCT was 0.9% (9/982), with none (0%) of the 607 infants of HBeAg-negative mothers and 9 (2.4%) of 375 infants of HBeAg-positive mothers acquiring HBV. All 9 HBV-infected infants were born to mothers with HBV DNA >2.75 × 106 IU/mL. Maternal HBV DNA levels >2 × 106 IU/mL were an independent risk factor (odds ratio, 10.627; 95% confidence interval, 2.135–∞) for immunoprophylaxis failure. Conclusions Earlier use (within 1 hour after birth) of HBIG and hepatitis B vaccine can provide better protection efficacy against MTCT of HBV.

scholarly journals Modelling hepatitis B virus infection and impact of timely birth dose vaccine: A comparison of two simulation models

PLoS ONE ◽  
2020 ◽  
Vol 15 (8) ◽  
pp. e0237525
Author(s):  
Margaret J. de Villiers ◽  
Ivane Gamkrelidze ◽  
Timothy B. Hallett ◽  
Shevanthi Nayagam ◽  
Homie Razavi ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Simulation Models ◽  
Hepatitis B Virus Infection ◽  
B Virus ◽  
Birth Dose ◽  
Dose Vaccine

scholarly journals Prevalence of Hepatitis B Virus Infection among Pregnant Women Attending Antenatal Clinics in Vientiane, Laos, 2008–2014

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Marc Choisy ◽  
Sengdeuane Keomalaphet ◽  
Kinnaly Xaydalasouk ◽  
Fabrice Quet ◽  
Vatthanaphone Latthaphasavang ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Pregnant Women ◽  
Democratic Republic ◽  
Perinatal Transmission ◽  
Hbv Vaccine ◽  
Annual Prevalence ◽  
B Virus ◽  
Birth Dose ◽  
Mother To Child

The Lao People’s Democratic Republic (PDR) is still considered a highly endemic country for hepatitis B, mainly due to perinatal transmission of hepatitis B virus (HBV), despite efforts made since 2004 for universal immunization of newborns. The prevalence of HBV surface antigen (HBsAg) carriage in pregnant women is a relevant marker for the risk of mother-to-child HBV transmission. This study aimed to assess the changes in prevalence of HBV infection among pregnant women attending the Mahosot Prenatal Clinic (Vientiane Capital). Methods. A retrospective study was performed in the Mahosot Hospital Laboratory to collect and analyze all the results of HBsAg testing in pregnant women from 2008 to 2014. Results. Of a total of 13,238 tested women of mean age of 26 years, 720 women (5,44% [95 CI: 5.1–5.8%]) were found HBsAg positive, the annual prevalence ranging from 4.6% to 6.2%. A slight but steady and significant decrease in prevalence over the 7 years of the study could be documented. Conclusion. Although below the 8% hyperendemic threshold, the HBsAg prevalence observed in pregnant women in Vientiane reflects a high risk of HBV perinatal transmission and call for a widespread infant immunization with an HBV vaccine birth dose.

Sign in / Sign up

Export Citation Format

Share Document